The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
WM-CART-02
Phase 1 mab active
Quick answer
The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for Lymphoma is a Phase 1 program (mab) at Sinobioway Cell Therapy Co., with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sinobioway Cell Therapy Co.,
- Indication
- Lymphoma
- Phase
- Phase 1
- Modality
- mab
- Status
- active